Skip to main content
. Author manuscript; available in PMC: 2024 Jun 24.
Published in final edited form as: J Am Soc Cytopathol. 2022 Nov 18;12(2):105–111. doi: 10.1016/j.jasc.2022.11.002

Table 1.

Summary of key radiologic, pathologic, and molecular findings of isthmus nodule.

Examination date Ultrasound Cytopathology/Surgical pathology ThyroSeq v3 molecular details ThyroSeq v3 molecular result
October 2018 Thyroid isthmus nodule, solid and hypoechoic, 1.8 cm FNA: AUS Low-level, isolated EIF1AX splice-site mutation (p.A113_splice), AF 11% Currently negative; PCN: Low (5%−10%)
December 2019 Thyroid isthmus nodule, solid and hypoechoic, 2.1 cm FNA: AUS Low-level, isolated EIF1AX splice-site mutation (p.A113_splice), AF 25% Currently negative; PCN: Low (5%−10%)
December 2021 Thyroid isthmus nodule, solid and hypoechoic, 2.7 cm; TR-3 FNA: AUS Low-level, isolated EIF1AX splice-site mutation (p.A113_splice), AF 12%
Non-V600E BRAF mutation (p.L597Q), AF 1%		 Positive; PCN: Intermediate-high (50%−60%)
April 2022 — SP: Encapsulated noninvasive, oncocytic solid subtype papillary thyroid carcinoma with increased mitotic activity, 2.7 cm EIF1AX splice-site mutation (p.A113_splice), AF 64% —

Abbreviations: AF, allelic frequency; AUS, atypia of undetermined significance; FNA, fine-needle aspiration; PCN, probability of cancer or noninvasive follicular thyroid neoplasm with papillary-like nuclear features; SP, surgical pathology; TR, thyroid imaging reporting and data system.